Search

Your search keyword '"Ugurel, Selma"' showing total 1,079 results

Search Constraints

Start Over You searched for: Author "Ugurel, Selma" Remove constraint Author: "Ugurel, Selma"
1,079 results on '"Ugurel, Selma"'

Search Results

7. CellViT: Vision Transformers for Precise Cell Segmentation and Classification

8. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg

10. Early versus late response to PD-1-based immunotherapy in metastatic melanoma

11. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas

12. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

13. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

16. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

18. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

19. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

20. Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG

22. Ten recommendations for sarcoma surgery: consensus of the surgical societies based on the German S3 guideline “Adult Soft Tissue Sarcomas”

23. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM

24. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

25. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study

26. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

27. Characterisation and outcome of RAC1 mutated melanoma

28. Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

29. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

30. Cutaneous Aspects of Leukemia

31. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study

32. Clinical determinants of long-term survival in metastatic uveal melanoma

33. Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

35. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events

37. Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma

41. S1‐Leitlinie Talgdrüsenkarzinom

42. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

43. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

46. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases

48. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

50. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Catalog

Books, media, physical & digital resources